FDA Approves LEQEMBI IQLIK Subcutaneous Autoinjector for Maintenance Dosing in Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved LEQEMBI®...
Injection Reactions
Advertisement
Advertisement
